Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday. Biogen reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion, according to data from Benzinga Pro. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 ...